Targeting Src Family Kinases Inhibits Bevacizumab-Induced Glioma Cell Invasion

Huveldt, Deborah; Lewis-Tuffin, Laura J.; Carlson, Brett L.; Schroeder, Mark A.; Rodriguez, Fausto; Giannini, Caterina; Galanis, Evanthia; Sarkaria, Jann N.; Anastasiadis, Panos Z.
February 2013
PLoS ONE;Feb2013, Vol. 8 Issue 2, p1
Academic Journal
Anti-VEGF antibody therapy with bevacizumab provides significant clinical benefit in patients with recurrent glioblastoma multiforme (GBM). Unfortunately, progression on bevacizumab therapy is often associated with a diffuse disease recurrence pattern, which limits subsequent therapeutic options. Therefore, there is an urgent need to understand bevacizumab's influence on glioma biology and block it's actions towards cell invasion. To explore the mechanism(s) of GBM cell invasion we have examined a panel of serially transplanted human GBM lines grown either in short-term culture, as xenografts in mouse flank, or injected orthotopically in mouse brain. Using an orthotopic xenograft model that exhibits increased invasiveness upon bevacizumab treatment, we also tested the effect of dasatinib, a broad spectrum SFK inhibitor, on bevacizumab-induced invasion. We show that 1) activation of Src family kinases (SFKs) is common in GBM, 2) the relative invasiveness of 17 serially transplanted GBM xenografts correlates strongly with p120 catenin phosphorylation at Y228, a Src kinase site, and 3) SFK activation assessed immunohistochemically in orthotopic xenografts, as well as the phosphorylation of downstream substrates occurs specifically at the invasive tumor edge. Further, we show that SFK signaling is markedly elevated at the invasive tumor front upon bevacizumab administration, and that dasatinib treatment effectively blocked the increased invasion induced by bevacizumab. Our data are consistent with the hypothesis that the increased invasiveness associated with anti-VEGF therapy is due to increased SFK signaling, and support testing the combination of dasatinib with bevacizumab in the clinic.


Related Articles

  • CT322, a VEGFR-2 antagonist, demonstrates anti-glioma efficacy in orthotopic brain tumor model as a single agent or in combination with temozolomide and radiation therapy. Waters, J.; Sanchez, Carlos; Sahin, Ayguen; Futalan, Diahnn; Gonda, David; Scheer, Justin; Akers, Johnny; Palanichamy, Kamalakannan; Waterman, Peter; Chakravarti, Arnab; Weissleder, Ralph; Morse, Brent; Marsh, Nick; Furfine, Eric; Chen, Clark; Carvajal, Irvith; Carter, Bob // Journal of Neuro-Oncology;Oct2012, Vol. 110 Issue 1, p37 

    Glioblastomas are among the most aggressive human cancers, and prognosis remains poor despite presently available therapies. Angiogenesis is a hallmark of glioblastoma, and the resultant vascularity is associated with poor prognosis. The proteins that mediate angiogenesis, including vascular...

  • Angiogenic Signalling Pathways Altered in Gliomas: Selection Mechanisms for More Aggressive Neoplastic Subpopulations with Invasive Phenotype. Bulnes, Susana; Bengoetxea, Harkaitz; Ortuzar, Naiara; Argandontilde;a, Enrike G.; Garcia-Blanco, Á lvaro; Rico-Barrio, Irantzu; Lafuente, José V. // Journal of Signal Transduction;2012, p1 

    The angiogenesis process is a key event for glioma survival, malignancy and growth. The start of angiogenesis is mediated by a cascade of intratumoural events: alteration of the microvasculature network; a hypoxic microenvironment; adaptation of neoplastic cells and synthesis of pro-angiogenic...

  • Are epsins a therapeutic target for tumor angiogenesis? Klauber-DeMore, Nancy // Journal of Clinical Investigation;Dec2012, Vol. 122 Issue 12, p17 

    Solid tumor growth requires the formation of new blood vessels to supply nutrients and oxygen to the malignant cells; one approach to cancer therapy is to block this process by inhibiting VEGF signaling. In this issue of the JCI, Pasula et al. demonstrate a surprising role of epsins -- proteins...

  • Inhibition of VEGF expression through blockade of Hif1α and STAT3 signalling mediates the anti-angiogenic effect of melatonin in HepG2 liver cancer cells. Carbajo-Pescador, S; Ordoñez, R; Benet, M; Jover, R; García-Palomo, A; Mauriz, J L; González-Gallego, J // British Journal of Cancer;7/9/2013, Vol. 109 Issue 1, p83 

    Background:Hepatocellular carcinoma (HCC) growth relies on angiogenesis via vascular endothelial growth factor (VEGF) release. Hypoxia within tumour environment leads to intracellular stabilisation of hypoxia inducible factor 1 alpha (Hif1α) and signal transducer and activator of...

  • Emodin inhibits the proliferation of PC3 prostate cancer cells in vitro via the Notch signaling pathway. GANG DENG; XIANG JU; QI MENG; ZHI-JIAN YU; LI-BIN MA // Molecular Medicine Reports;2015, Vol. 12 Issue 3, p4427 

    The aim of the present study was to examine the anticarcinogenic effects of emodin on the Notch signaling pathway and vascular endothelial growth factor (VEGF) in the PC3 androgen-independent prostate cancer cell line in vitro. The cell viability was assessed using an 3-(4,5)-dime...

  • Xanthatin, a novel potent inhibitor of VEGFR2 signaling, inhibits angiogenesis and tumor growth in breast cancer cells. Yao Yu; Jing Yu; Chong Gang Pei; Yun Yan Li; Ping Tu; Gui Ping Gao; Yi Shao // International Journal of Clinical & Experimental Medicine;2015, Vol. 8 Issue 9, p10355 

    Anti-angiogenesis targeting vascular endothelial growth factor receptor 2 (VEGFR2) has emerged as an important tool for cancer treatment. In this study, we described a novel VEGFR2 inhibitor, xanthatin, which inhibits tumor angiogenesis and growth. The biochemical profiles of xanthatin were...

  • TGF-Beta Suppresses VEGFA-Mediated Angiogenesis in Colon Cancer Metastasis. Geng, Liying; Chaudhuri, Anathbandhu; Talmon, Geoffrey; Wisecarver, James L.; Wang, Jing // PLoS ONE;Mar2013, Vol. 8 Issue 3, p1 

    The FET cell line, derived from an early stage colon carcinoma, is non-tumorigenic in athymic nude mice. Engineered FET cells that express TGF-α (FETα) display constitutively active EGFR/ErbB signaling. These cells readily formed xenograft tumors in athymic nude mice. Importantly, FETα...

  • The Complexities of Resistance to Bevacizumab. Shen, Han; McDonald, Kerrie L. // Journal of Cancer Therapy;Oct2012, Vol. 3 Issue 5, p491 

    Glioblastoma is a highly malignant primary tumor of the central nervous system tumor with a poor survival rate. The treatment of glioblastoma is shifting from a purely cytotoxic approach to one that incorporates anti-angiogenic agents. Bevacizumab (Avastin®; Roche) was approved in the United...

  • Effects of SC-560 in Combination with Cisplatin or Taxol on Angiogenesis in Human Ovarian Cancer Xenografts. Wei Li; Liang Wan; Ling-Yun Zhai; Jane Wang // International Journal of Molecular Sciences;Oct2014, Vol. 15 Issue 10, p19265 

    This study was designed to evaluate the effect of cyclooxygenase-1 (COX-1) inhibitor, SC-560, combined with cisplatin or taxol, on angiogenesis in human ovarian cancer xenografts. Mice were treated with intraperitoneal (i.p.) injections of SC-560 6 mg/kg/day, i.p. injections of cisplatin 3 mg/kg...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics